Sp399
LYNCH SYNDROME VACCINE: BENCH TO BEDSIDE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates. These state-of-the art lectures provide a bench to bedside insights into how basic and translational researchers can impact precision gastrointestinal oncology.
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates. These state-of-the art lectures provide a bench to bedside insights into how basic and translational researchers can impact precision gastrointestinal oncology.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates…
